Website profile

Endpoints News

Biotech and pharma business news, with a focus on the science, people and money that drive the industry.

  • 94articles · 30d
  • 1+ day agolatest article
  • Aug 17, 2026earliest in window
  • 95%with images
  • 86avg words
articles per day
Categories
  • Health & Wellness 74
  • Medical 63
  • Science & Technology 31
  • Health 30
  • Economy, Business & Finance 27
  • Finance & Business 21
  • Business & Industrial 15
  • Science & Nature 7

Please confirm you are human

This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.

A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.

Hold with a pointer, or hold Space or Enter.

News

Endpoints News
endpoints.news > encoded-closes-275m-series-f-for-dravet-syndrome-drug

Encoded closes $275M Series F for Dravet syndrome drug

4+ day, 23+ hour ago   (75+ words) Endpoints News En­cod­ed clos­es $275M Se­ries F for Dravet syn­drome drug En­cod­ed Ther­a­peu­tics has tacked on $275 mil­lion in new cap­i­tal, clos­ing a Se­ries F round led…...

Endpoints News
endpoints.news > nodthera-a-decade-old-nlrp3-player-plans-phase-3-and-a-rebrand

NodThera, a decade-old NLRP3 player, plans Phase 3 and a rebrand

5+ day, 5+ hour ago   (82+ words) Endpoints News NodThera, a decade-old NL­RP3 play­er, plans Phase 3 and a re­brand Af­ter tin­ker­ing with the bi­ol­o­gy of the broad­ly ap­peal­ing an­ti-in­flam­ma­to­ry NL­RP3 path…...

Google News
endpoints.news > beeline-medicines-reports-promising-phase-2-lupus-data

Beeline Medicines reports promising Phase 2 lupus data

5+ day, 5+ hour ago   (81+ words) Beeline Medicines reports promising mid-stage lupus data Endpoints News Bee­line Med­i­cines re­ports promis­ing mid-stage lu­pus da­ta The busi­ness of ad­vanc­ing shelved phar­ma as­sets con­tin­ues to reap…...

Endpoints News
endpoints.news > cancer-biotech-twostep-gets-62-5m-to-take-twist-on-adcs-into-clinic

Exclusive: Cancer biotech TwoStep gets $62.5M to take twist on ADCs into clinic

5+ day, 5+ hour ago   (92+ words) Endpoints News Ex­clu­sive: Can­cer biotech TwoStep gets $62.5M to take twist on AD­Cs in­to clin­ic Pfiz­er and Mer­ck KGaA’s ven­ture groups are back­ing a nim­ble can­cer start­up tak…...

Endpoints News
endpoints.news > kura-oncology-spins-out-diabetes-pipeline-with-50m-and-lillys-help

Kura Oncology spins out diabetes pipeline with $50M and Lilly's help

5+ day, 5+ hour ago   (79+ words) Kura Oncology spins out diabetes pipeline with $50M and Lilly’s help Endpoints News Ku­ra On­col­o­gy spins out di­a­betes pipeline with $50M and Lil­ly's help Ku­ra On­col­o­gy, the mak­er of the…...

Endpoints News
endpoints.news > moonwalk-raises-70-million-to-test-sirna-treatment-for-obesity

Moonwalk raises $70M to test siRNA treatment for obesity

6+ day, 4+ hour ago   (75+ words) Endpoints News Moon­walk rais­es $70M to test siR­NA treat­ment for obe­si­ty Moon­walk Bio­sciences is head­ing to the clin­ic with an obe­si­ty pro­gram and has raised $70 mil­lion for…...

Endpoints News
endpoints.news > diabetes-cell-therapy-biotechs-sernova-and-seraxis-to-merge

Diabetes cell therapy biotechs Sernova and Seraxis to merge

6+ day, 5+ hour ago   (79+ words) Endpoints News Di­a­betes cell ther­a­py biotechs Ser­no­va and Ser­ax­is to merge Two com­pa­nies that have spent decades try­ing to de­vel­op cell ther­a­pies for di­a…...

Endpoints News
endpoints.news > abbvie-allied-adarx-aims-for-ipo-with-3-drugs-in-the-clinic

AbbVie-allied ADARx aims to go public with 3 drugs in the clinic

1+ week, 2+ day ago   (90+ words) Endpoints News Ab­b­Vie-al­lied ADARx aims to go pub­lic with 3 drugs in the clin­ic RNA in­ter­fer­ence com­pa­ny ADARx Phar­ma­ceu­ti­cals re­vealed its in­ten­tions to go…...

Endpoints News
endpoints.news > alumis-tyk2-drug-fails-in-lupus-trial-ceo-sees-clear-path-forward

Alumis falls after TYK2 pill fails lupus study, but CEO sees 'clear path forward"

1+ week, 6+ day ago   (80+ words) Alumis falls after TYK2 pill fails lupus study, but CEO sees 'clear path forward' Endpoints News Alu­mis falls af­ter TYK2 pill fails lu­pus study, but CEO sees 'clear path for­ward' Alu­mis’ lead drug pro­gram suf­fered…...

Endpoints News
endpoints.news > roivants-dermatomyositis-drug-lisraya-snags-fda-approval

Roivant’s road to a potential blockbuster begins with Lisraya FDA approval

2+ week, 3+ day ago   (86+ words) Endpoints News Roivant’s road to a po­ten­tial block­buster be­gins with Lis­raya FDA ap­proval The FDA ap­proved Roivant’s der­mato­myosi­tis drug bre­poc­i­tinib on Wednes­day, the first ma­jor…...